Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 7.1% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded down 7.1% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $6.07 and last traded at $6.12. 4,751,581 shares were traded during mid-day trading, a decline of 19% from the average session volume of 5,863,063 shares. The stock had previously closed at $6.59.

Specifically, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several analyst reports. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Needham & Company LLC lowered their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Performance

The stock has a 50 day moving average price of $7.00 and a two-hundred day moving average price of $8.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -3.82 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company’s revenue was up 30.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.38) earnings per share. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the period. Amalgamated Bank lifted its stake in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the period. Oxford Wealth Group LLC bought a new position in Recursion Pharmaceuticals during the first quarter worth about $106,000. Finally, Midwest Financial Group LLC acquired a new position in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $90,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.